Unsere Publikationen

Extensive T-Cell Profiling Following SARS-CoV-2 mRNA Vaccination in Multiple Sclerosis Patients Treated with DMTs

Link
https://doi.org/10.3390/pathogens14030235
Tags
Multiple Sklerose
Jahr
2025
Autoren
Solchenberger H, Odendahl M, Schriefer D, Proschmann U, Rahbani GKa, Ziemssen T, Akgün K.
Verlag
Pathogens. 2025; 14(3):235.
Zum Eintrag

Long-term efficacy and safety of alemtuzumab in participants with highly active MS: TOPAZ clinical trial and interim analysis of TREAT-MS real-world study

Link
https://doi.org/10.1177/17562864241306575
Tags
Multiple SkleroseMS Behandlung
Jahr
2025
Autoren
Ziemssen T, Bass AD, Van Wijmeersch B, Eichau S, Richter S, Hoffmann F, Armstrong NM, Chirieac M, Cunha-Santos J, Singer BA.
Verlag
Ther Adv Neurol Disord. 2025 Feb 10;18:17562864241306575.
Zum Eintrag

Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS

Link
https://doi.org/10.1212/WNL.0000000000210142
Tags
Multiple SkleroseMS Behandlung
Jahr
2025
Autoren
Cerqueira JJ, Berthele A, Cree BAC, Filippi M, Pardo G, Pearson OR, Traboulsee A, Ziemssen T, Vollmer T, Bernasconi C, Mandel CR, Kulyk I, Chognot C, Raposo C, Schneble HM, Thanei GA, Incera E, Havrdová EK.
Verlag
Neurology. 2025 Feb 25;104(4):e210142.
Zum Eintrag

A plain language summary of a study exploring the experiences of people with relapsing–remitting multiple sclerosis: what symptoms and impacts of the disease matter most and how can they be evaluated better?

Link
https://doi.org/10.1080/17582024.2024.2441068
Tags
Multiple SkleroseMS Behandlung
Jahr
2025
Autoren
Barrett Amy, Olayinka-Amao O, Ziemssen T, Bharadia T, Henke C, Kamudoni P.
Verlag
Neurodegenerative Disease Management, January, 1–8.
Zum Eintrag

Cost–consequence analysis of early vs. delayed natalizumab use in highly active relapsing–remitting multiple sclerosis: a simulation study

Link
https://doi.org/10.1007/s00415-024-12723-4
Tags
Multiple SkleroseMS BehandlungManagement & ScienceGesundheitsökonomie
Jahr
2025
Autoren
Inojosa H, Schriefer D, Ness NH, Dillenseger A, Akgün K, Ziemssen T.
Verlag
J Neurol. 2025 Jan 17;272(2):153.
Zum Eintrag

RENEWED: A follow-up study of the opicinumab phase 2 RENEW study in participants with acute optic neuritis

Link
https://doi.org/10.1016/j.msard.2024.106185
Tags
MS BehandlungAndere
Jahr
2024
Autoren
Aktas O, Ziemssen F, Ziemssen T, Klistorner A, Butzkueven H, Izquierdo G, Leocani L, Balcer LJ, Galetta SL, Castrillo-Viguera C, Bradley DP, Naylor ML, Belachew S, Franchimont N, Zhu B, Cheng W; RENEWED Investigators.
Verlag
Mult Scler Relat Disord. 2024 Nov 24;93:106185.
Zum Eintrag

Challenges and implications of anti-JCV antibody serology variability among different assays in natalizumab treatment: A call for standardization and transparency in clinical practice

Link
https://doi.org/10.1177/13524585241300972
Tags
Multiple SkleroseMS Behandlung
Jahr
2024
Autoren
Inojosa H, Kather A, Akgün K, Ziemssen T.
Verlag
Mult Scler. 2024 Nov 23:13524585241300972.
Zum Eintrag

MS brain health quality standards: a survey on the reality in clinical practice in Germany

Link
https://doi.org/10.1186/s42466-024-00333-4
Tags
Multiple SkleroseMS Behandlung
Jahr
2024
Autoren
Voigt I, Akgün K, Inojosa H, Haas J, Temmes H, Meuth SG, Giovannoni G, Ziemssen T.
Verlag
Neurol Res Pract. 2024 Nov 18;6(1):59.
Zum Eintrag
1 2 3 4 5

Publikationen durchsuchen

Publikationen filtern

Filter
Tags
Multiple Sklerose
MS Behandlung
Mobilität
Autonomes Nervensystem & Neuroendokrinologie
Neuroimmunologie
Herzratenvariabilität
Baroreflexsensitivität
Management & Science
eHealth
Gesundheitsökonomie
Andere
Zeige alleVerstecke
Jahr
-